Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 14, 2018 - Issue
Submit an article Journal homepage
162
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease

Robert A Hauser1 Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL, USACorrespondence[email protected]
,
Aaron Ellenbogen2 Quest Research Institute, Bingham Farms, MI, USA
,
Sarita Khanna3 Impax Laboratories, Inc., Hayward, CA, USA
,
Suneel Gupta3 Impax Laboratories, Inc., Hayward, CA, USA
&
Nishit B Modi3 Impax Laboratories, Inc., Hayward, CA, USA
Pages 839-845 | Published online: 22 Mar 2018

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Robert A. Hauser, Peter A. LeWitt & Cynthia L. Comella. (2021) On demand therapy for Parkinson’s disease patients: Opportunities and choices. Postgraduate Medicine 133:7, pages 721-727.
Read now
Thomas Müller & Jan-Dominique Möhr. (2018) Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease. Expert Opinion on Pharmacotherapy 19:18, pages 2063-2071.
Read now

Articles from other publishers (7)

Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case & Nir Giladi. (2022) The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program. Frontiers in Neurology 13.
Crossref
Nicola L. Brice, Hans H. Schiffer, Holger Monenschein, Victoria J. Mulligan, Keith Page, Justin Powell, Xiao Xu, Toni Cheung, J. Russell Burley, Huikai Sun, Louise Dickson, Sean T. Murphy, Nidhi Kaushal, Steve Sheardown, Jason Lawrence, Yun Chen, Darian Bartkowski, Anne Kanta, Joseph Russo, Natalie Hosea, Lee A. Dawson, Stephen H. Hitchcock & Mark B. Carlton. (2021) Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. Journal of Pharmacology and Experimental Therapeutics 377:3, pages 407-416.
Crossref
Sarah Horn, Hayley Richardson, Sharon X. Xie, Daniel Weintraub & Nabila Dahodwala. (2019) Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism & Related Disorders 69, pages 119-124.
Crossref
Sebastian Castano-Candamil, Mara Vaihinger & Michael Tangermann. (2019) A simulated environment for early development stages of reinforcement learning algorithms for closed-loop deep brain stimulation. A simulated environment for early development stages of reinforcement learning algorithms for closed-loop deep brain stimulation.
Kirsten E. Zeuner, Eva Schäffer, Franziska Hopfner, Norbert Brüggemann & Daniela Berg. (2019) Progress of Pharmacological Approaches in Parkinson's Disease. Clinical Pharmacology & Therapeutics 105:5, pages 1106-1120.
Crossref
Feng Zhou, Jing Ju, Yongjun Fang, Xiaoxuan Fan, Shuguang Yan, Qiang Wang, Pengfang Wei, Fuliang Duan, Feng Miao, Zhenyuan Hu & Maode Wang. (2018) Salidroside protected against MPP + ‐induced Parkinson's disease in PC12 cells by inhibiting inflammation, oxidative stress and cell apoptosis . Biotechnology and Applied Biochemistry 66:2, pages 247-253.
Crossref
Emma L. Lane. (2019) L-DOPA for Parkinson's disease-a bittersweet pill. European Journal of Neuroscience 49:3, pages 384-398.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.